A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

Modulating aberrant transcription of oncogenes is a relatively unexplored opportunity in cancer therapeutics. In approximately 10% of multiple myelomas, the initiating oncogenic event is translocation of musculoaponeurotic fibrosarcoma oncogene homolog (MAF), a transcriptional activator of key targe...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Annunziata, Christina M., Hernandez, Lidia, Davis, R. Eric, Zingone, Adriana, Lamy, Laurence, Lam, Lloyd T., Hurt, Elaine M., Shaffer, Arthur L., Kuehl, W. Michael, Staudt, Louis M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2011
Aiheet:
Lymphoid Neoplasia
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3062408/
https://ncbi.nlm.nih.gov/pubmed/21163924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-04-278788
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia